- Home
- PHAR vs AACT Comparison
PHAR vs AACT Comparison
Compare PHAR & AACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- AACT
- Stock Information
- Founded
- PHAR 1988
- AACT 2021
- Country
- PHAR Netherlands
- AACT United States
- Employees
- PHAR N/A
- AACT N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- AACT
- Sector
- PHAR Health Care
- AACT
- Exchange
- PHAR Nasdaq
- AACT Nasdaq
- Market Cap
- PHAR 718.1M
- AACT 697.5M
- IPO Year
- PHAR N/A
- AACT 2023
- Fundamental
- Price
- PHAR $11.24
- AACT $11.51
- Analyst Decision
- PHAR Strong Buy
- AACT
- Analyst Count
- PHAR 3
- AACT 0
- Target Price
- PHAR $30.00
- AACT N/A
- AVG Volume (30 Days)
- PHAR 3.1K
- AACT 694.0K
- Earning Date
- PHAR 05-08-2025
- AACT 01-01-0001
- Dividend Yield
- PHAR N/A
- AACT N/A
- EPS Growth
- PHAR N/A
- AACT N/A
- EPS
- PHAR N/A
- AACT 0.36
- Revenue
- PHAR $320,708,000.00
- AACT N/A
- Revenue This Year
- PHAR $13.31
- AACT N/A
- Revenue Next Year
- PHAR $7.68
- AACT N/A
- P/E Ratio
- PHAR N/A
- AACT $31.66
- Revenue Growth
- PHAR 24.13
- AACT N/A
- 52 Week Low
- PHAR $6.65
- AACT $10.64
- 52 Week High
- PHAR $11.07
- AACT $11.45
- Technical
- Relative Strength Index (RSI)
- PHAR 69.87
- AACT 86.09
- Support Level
- PHAR $10.02
- AACT $11.27
- Resistance Level
- PHAR $10.89
- AACT $11.29
- Average True Range (ATR)
- PHAR 0.23
- AACT 0.04
- MACD
- PHAR 0.11
- AACT 0.02
- Stochastic Oscillator
- PHAR 100.00
- AACT 96.67
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.